HC Wainwright Weighs in on Scholar Rock Q1 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Scholar Rock in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.76) for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Scholar Rock’s Q2 2027 earnings at ($0.71) EPS, Q3 2027 earnings at ($0.64) EPS and Q4 2027 earnings at ($0.55) EPS.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.30 million. During the same quarter in the prior year, the firm earned ($0.90) earnings per share.

A number of other equities research analysts also recently commented on SRRK. UBS Group reaffirmed a “buy” rating on shares of Scholar Rock in a research report on Tuesday, September 15th. Piper Sandler lifted their price objective on Scholar Rock from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, September 15th. TD Cowen reiterated a “buy” rating on shares of Scholar Rock in a research report on Monday, September 14th. Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. Finally, Citigroup increased their target price on Scholar Rock from $60.00 to $74.00 and gave the company a “buy” rating in a report on Monday, September 14th. Four research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $67.67.

Scholar Rock Stock Down 6.9%

Shares of Scholar Rock stock opened at $48.00 on Wednesday. Scholar Rock has a twelve month low of $28.97 and a twelve month high of $61.76. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The company’s 50 day moving average is $46.83 and its 200 day moving average is $48.22. The company has a market cap of $5.85 billion, a price-to-earnings ratio of -13.91 and a beta of 0.78.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Scholar Rock during the 2nd quarter valued at approximately $522,175,000. Redmile Group LLC boosted its position in shares of Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after purchasing an additional 3,845,775 shares during the period. Jupiter Topco LLC bought a new position in shares of Scholar Rock in the second quarter worth approximately $123,279,000. Bank of America Corp DE purchased a new stake in shares of Scholar Rock in the second quarter worth $53,474,000. Finally, Eagle Health Investments LP bought a new stake in shares of Scholar Rock during the 2nd quarter valued at $30,540,000. Institutional investors own 91.08% of the company’s stock.

Insiders Place Their Bets

In related news, Director Srinivas Akkaraju purchased 146,970 shares of the business’s stock in a transaction on Monday, October 26th. The stock was acquired at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the acquisition, the director owned 6,380,517 shares of the company’s stock, valued at approximately $265,365,702.03. This trade represents a 2.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 10.30% of the company’s stock.

Key Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Scholar Rock reported a Q3 loss of $0.81 per share, beating estimates of $0.85–$0.87, and revenue of $0.57 million, above the $0.30 million forecast. The quarter included the company’s first product revenue, a milestone that may support investor optimism about commercialization. Q3 results Company results and business highlights
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 target. Its 2027 quarterly estimates project progressively smaller losses, from $0.76 per share in Q1 to $0.55 in Q4. Analyst coverage
• Negative Sentiment: Despite the earnings beat and new product revenue, Scholar Rock remains loss-making; HC Wainwright’s estimates still show quarterly losses throughout 2027. This keeps execution and future commercialization important considerations for investors.

Scholar Rock Company Profile

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.